Cheng Y, Tian H. Current development status of MEK-inhibitors. Molecules. 2017. https://doi.org/10.3390/molecules22101551.

Article  PubMed  PubMed Central  Google Scholar 

Hu X, Li W, Zeng K, et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 2023;21(1):230.

CAS  PubMed  PubMed Central  Google Scholar 

Li W, Mao Y, Kang Z, et al. A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated [abstract no. 499O]. Ann Oncol. 2023;34(Suppl 2):S391–2.

Google Scholar 

Cao X-X, Zhu Q, Cai Z, et al. A multi-center, open-label, single-arm phase II study to evaluate the efficacy and safety of FCN-159 in adults with histiocytic neoplasms [abstract no. P559]. HemaSphere. 2024;8(Suppl 1):929–31.

Google Scholar 

Xu Z, Zhou J, Chen Y, et al. MEK inhibitors for the treatment of extracranial arteriovenous malformations. CJPRS. 2023;5(3):141–4.

CAS  Google Scholar 

Shanghai Fosun Pharmaceutical. Fosun Pharma's self-developed innovative drug luvometinib tablet approved in China [media release]. 29 May 2025. https://www.fosunpharma.com/.

Lin S, Zhao X, Zhou Z, et al. FCN-159: A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors [abstract no. 1951]. Cancer Res. 2020;80(16 Suppl).

Shanghai Fosun Pharmaceutical. Luvometinib: Chinese prescribing information. Shanghai: Shanghai Fosun Pharmaceutical; 2025.

Google Scholar 

National Medical Products Administration. The State Food and Drug Administration approved the marketing of luvometinib tablets [media release]. 29 May 2025. https://www.nmpa.gov.cn/.

Li J, Tan Y, Li K, et al. Effect of food (low and high fat) on pharmacokinetics of FCN-159, a selective MEK inhibitor, in healthy Chinese males. Adv Ther. 2023;40(3):1074–86.

CAS  PubMed  Google Scholar 

Mao L, Guo J, Zhu L, et al. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2022;175:125–35.

CAS  PubMed  Google Scholar 

Gu J, Mao L, Guo J, et al. FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: a phase 1B dose-expansion study [abstract no. 3095]. J Clin Oncol. 2024;42(16 Suppl).

Zhang R, Liu R, Yu J, et al. The efficacy and safety of luvometinib (FCN-159) in pediatric patients with refractory/relapsed Langerhans cell histiocytosis: a multi-center, open-label, single-arm phase II study [abstract no. PF502]. In: EHA 2025. 2025.

Wang J, Li W, Zeng K, et al. Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study [abstract no. 10044]. J Clin Oncol. 2025;43(16 Suppl).

Wang J, Li W, Zeng K, et al. Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: results from a phase 2 trial [abstract no. 3096]. J Clin Oncol. 2024;42(16 Suppl).

Hu X. Luvometinib (FCN-159) in adult NF1 patients: efficacy and safety outcomes from a multi-center, open-label, single-arm phase II trial [abstract plus poster 4921]. In: NF CONFERENCE. 2025.